Overview

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.

Phase:

Phase 3

Details

Lead Sponsor:

UCB BIOSCIENCES GmbH

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

N 0437
Pramipexole
Ropinirole
Rotigotine